Flavokawain A is a natural inhibitor of PRMT5 in bladder cancer

被引：0
|
作者：
Shuangjie Liu
Zhuonan Liu
Chiyuan Piao
Zhe Zhang
Chuize Kong
Lei Yin
Xi Liu
机构：
[1] The First Hospital of China Medical University,Department of Urology
来源：
Journal of Experimental & Clinical Cancer Research | / 41卷
关键词：
Protein arginine methyltransferase; Flavokawain A; Bladder cancer; Methylation disorder; Arginine methylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Decreased expression of PRMT5 is associated with prostate cancer
    Guo, CC
    Zhang, X
    Yee, H
    Chiriboga, L
    Melamed, J
    Lee, P
    MODERN PATHOLOGY, 2005, 18 : 143A - 143A
  • [12] Role of PRMT5 in neuroendocrine prostate cancer development
    Nam, Hye Seung
    Deng, Xuehong
    Hu, Chang-Deng
    CANCER RESEARCH, 2024, 84 (06)
  • [13] Combination of TGF-β inhibitor and PRMT5 inhibitor prolongs the survival rate of murine pancreatic cancer model
    Hong, Eunji
    Park, Sujin
    An, Haein
    Thangue, Nick L.
    Kim, Seongjin
    CANCER SCIENCE, 2024, 115 : 1925 - 1925
  • [14] Decreased expression of PRMT5 is associated with prostate cancer
    Guo, CC
    Zhang, X
    Yee, H
    Chiriboga, L
    Melamed, J
    Lee, P
    LABORATORY INVESTIGATION, 2005, 85 : 143A - 143A
  • [15] PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
    Welliver, Meng
    Jin, Feng
    Otterson, Gregory
    Carbone, David
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S844 - S844
  • [16] A new move for PRMT5
    Joanna E. Huddleston
    Nature Reviews Molecular Cell Biology, 2011, 12 : 76 - 76
  • [17] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells
    Suresh, Samyuktha
    McPherson, Lisa A.
    Ford, James M.
    CANCER RESEARCH, 2024, 84 (06)
  • [18] A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models
    Brehmer, Dirk
    Wu, Tongfei
    Mannens, Geert
    Beke, Lijs
    Vinken, Petra
    Gaffney, Dana
    Sun, Weimei
    Pande, Vineet
    Thuring, Jan-Willem
    Millar, Hillary
    Poggesi, Italo
    Somers, Ivan
    Boeckx, An
    Parade, Marc
    van Heerde, Erika
    Nys, Thomas
    Yanovich, Carol
    Herkert, Barbara
    Verhulst, Tinne
    Du Jardin, Marc
    Meerpoel, Lieven
    Moy, Christopher
    Diels, Gaston
    Viellevoye, Marcel
    Schepens, Wim
    Poncelet, Alain
    Linders, Joannes T.
    Lawson, Edward C.
    Edwards, James P.
    Chetty, Dushen
    Laquerre, Sylvie
    Lorenzi, Matthew V.
    CANCER RESEARCH, 2017, 77
  • [19] Epigenetic drug screening defines a PRMT5 inhibitor-sensitive pancreatic cancer subtype
    Orben, Felix
    Lankes, Katharina
    Schneeweis, Christian
    Hassan, Zonera
    Jakubowsky, Hannah
    Krauss, Lukas
    Boniolo, Fabio
    Schneider, Carolin
    Schaefer, Arlett
    Murr, Janine
    Schlag, Christoph
    Kong, Bo
    Oellinger, Rupert
    Wang, Chengdong
    Beyer, Georg
    Mahajan, Ujjwal M.
    Xue, Yonggan
    Mayerle, Julia
    Schmid, Roland M.
    Kuster, Bernhard
    Rad, Roland
    Braun, Christian J.
    Wirth, Matthias
    Reichert, Maximilian
    Saur, Dieter
    Schneider, Guenter
    JCI INSIGHT, 2022, 7 (10)
  • [20] A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models
    Chan-Penebre, Elayne
    Kuplast, Kristy G.
    Majer, Christina R.
    Boriack-Sjodin, P. Ann
    Wigle, Tim J.
    Johnston, L. Danielle
    Rioux, Nathalie
    Munchhof, Michael J.
    Jin, Lei
    Jacques, Suzanne L.
    West, Kip A.
    Lingaraj, Trupti
    Stickland, Kimberly
    Ribich, Scott A.
    Raimondi, Alejandra
    Scott, Margaret Porter
    Waters, Nigel J.
    Pollock, Roy M.
    Smith, Jesse J.
    Barbash, Olena
    Pappalardi, Melissa
    Ho, Thau F.
    Nurse, Kelvin
    Oza, Khyati P.
    Gallagher, Kathleen T.
    Kruger, Ryan
    Moyer, Mikel P.
    Copeland, Robert A.
    Chesworth, Richard
    Duncan, Kenneth W.
    NATURE CHEMICAL BIOLOGY, 2015, 11 (06) : 432 - +
12345